Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 279

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1

Kahan, Barry D., Julian, Bruce A., Pescovitz, Mark D., Vanrenterghem, Yves, Neylan, John·1999·Transplantation

Abstract

BACKGROUND: The novel agent sirolimus (SRL; Rapamune; rapamycin) inhibits the immune response by a mechanism distinct from those of calcineurin antagonists or antimetabolites. This randomized, controlled, multicenter, single blind, phase II trial examined the combination of SRL, steroids, and full versus reduced doses of cyclosporine (CsA) for prophylaxis of acute renal allograft rejection. METHODS: A total of 149 recipients of mismatched cadaveric- or living-donor primary renal allografts were randomized into six groups. Three groups received placebo or 1 or 3 mg/m2/day SRL, as well as steroids and full-dose CsA (Sandimmune). Three groups received steroids, reduced-dose CsA (target trough level 50% of full-dose range), and 1, 3, or 5 mg/m2/day SRL. RESULTS: The incidence of biopsy-proven acute rejection episodes within the first 6 months after transplant was reduced from 32.0% in the control group to 8.5% in patients receiving SRL (1 or 3 mg/m2/day) and full-dose Sandimmune CsA (P=0.018). Similar low rates of acute rejection episodes were observed among non-African-Americans, but not African-Americans, treated with SRL and reduced-dose Sandimmune CsA. Despite the augmented immunosuppression, 1-year patient and graft survival rates did not differ significantly across groups. Adverse effects attributable to CsA, including hypertension and new-onset diabetes mellitus, were not exacerbated by SRL. Except for an increased incidence of pneumonia among patients receiving full-dose CsA and 3 mg/m2/day SRL, the incidences of opportunistic infections were similar in all treatment groups. Although SRL produced more frequent, but reversible, hematological and lipid abnormalities, it had no apparent nephrotoxic effects to exacerbate CsA-induced renal dysfunction. CONCLUSIONS: SRL in combination with CsA and steroids not only lowers the incidence of biopsy-proven acute renal allograft rejection episodes, but also may permit CsA sparing, at least among Caucasian patients, without an increased risk of rejection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199911270-00016

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 279

Metadata

Authors
Kahan, B. D., Julian, B. A., Pescovitz, M. D., Vanrenterghem, Y., & Neylan, J.
Venue
Transplantation
Published
1999-11
Volume
68
Issue
10
Pages
1526-1532
ISSN
0041-1337 (ISSN-L)
OpenAlex
W1996524560
Cited by
279
References
21
FWCI
18.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1. https://app.cochat.ai/papers/10.1097/00007890-199911270-00016
The paper
Kahan, B. D., Julian, B. A., Pescovitz, M. D., Vanrenterghem, Y., & Neylan, J. (1999). SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1. Transplantation. https://doi.org/10.1097/00007890-199911270-00016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.